Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vaginal ring shows promise for birth control

NCT ID NCT06019533

Disease control Sponsor: Chemo Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new vaginal ring that releases the hormone levonorgestrel to prevent pregnancy. Over 1,000 women used the ring for 13 cycles. Researchers measured how well it worked and checked for side effects. The ring is designed to be a convenient, woman-controlled birth control method.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Levonorgestrel vaginal ring
What this could lead to
If successful, this could provide a new, effective birth control option that women can use themselves.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all populations. Side effects like irregular bleeding are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,039 people

The number who actually took part.

Started

Aug 2023

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At Visit 1a, subjects must meet ALL of the following criteria: 1. Sexually active, postmenarcheal and premenopausal female subjects at risk of pregnancy including breastfeeding women. 2. Women who either 1. have never used hormonal contraceptives before consent/assent (naïve users), or 2. have used hormonal contraceptives in the past, but have had a hormonal contraceptive-free period before consent/assent and a full menstrual cycle during the drug-free period (previous users) or 3. directly switch from another hormonal contraceptive (switchers). 3. Only for subjects who were not pregnant and did not use hormonal contraception during the last 6 months before consent/assent: Regular cycles (i.e. cycle length between 24 and 35 days) during the last 6 months. Exclusion Criteria: 1. Pregnancy or wish of pregnancy. 2. Subject is known to or suspected of not being able to comply with the trial protocol, the use of the trial medication or the use of the trial diary. 3. History of infertility. 4. Known bleeding disorder or history of unexplained bleeding or bruising within the last 12 months prior to V1a. 5. Unexplained amenorrhoea. 6. Abnormal finding on pelvic, breast or ultrasound examination that in the investigator's opinion contraindicates participation in the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Contraception are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contraception

Contacts and locations

Locations

  • LR-301/

    Móstoles, Madrid, 28938, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.